Theravance Biopharma (TBPH) Total Liabilities (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Total Liabilities of $472.3 million for Q1 2026, up 37.47% year-over-year from $343.6 million in Q1 2025, and down 2.73% quarter-over-quarter from $485.6 million in Q4 2025.
Theravance Biopharma (TBPH) Total Liabilities (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Total Liabilities for 14 consecutive years, with $472.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 37.47% year-over-year to $472.3 million; the TTM figure through Mar 2026 stood at $472.3 million (up 37.47% YoY), while the FY2025 annual figure was $485.6 million, up 37.1% from the prior year.
- Total Liabilities retreated to $472.3 million in Q1 2026 per TBPH's latest filing, from $485.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $763.5 million in Q3 2022 and bottomed at $343.6 million in Q1 2025.
- Historically, Total Liabilities has averaged $438.5 million across 5 years, with a median of $413.6 million in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 89.4% — and 2023, when it sank 45.83%.
- Theravance Biopharma's Total Liabilities stood at $607.4 million in 2022, then sank by 37.11% to $382.0 million in 2023, then declined by 7.29% to $354.2 million in 2024, then jumped by 37.1% to $485.6 million in 2025, then slipped by 2.73% to $472.3 million in 2026.
- Business Quant data shows TBPH's Total Liabilities at $472.3 million in Q1 2026, $485.6 million in Q4 2025, and $415.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 469.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 469.77 Mn |
| Mar 31, 2026 | 472.31 Mn |
| Dec 31, 2025 | 485.57 Mn |
| Sep 30, 2025 | 415.46 Mn |
| Jun 30, 2025 | 426.04 Mn |
| Mar 31, 2025 | 343.58 Mn |
| Dec 31, 2024 | 354.16 Mn |
| Sep 30, 2024 | 356.11 Mn |
| Jun 30, 2024 | 362.03 Mn |
| Mar 31, 2024 | 371.31 Mn |
| Dec 31, 2023 | 382.00 Mn |
| Sep 30, 2023 | 413.59 Mn |
| Jun 30, 2023 | 446.63 Mn |
| Mar 31, 2023 | 538.55 Mn |
| Dec 31, 2022 | 607.40 Mn |
| Sep 30, 2022 | 763.50 Mn |
| Jun 30, 2022 | 360.76 Mn |
| Mar 31, 2022 | 355.36 Mn |
| Dec 31, 2021 | 374.82 Mn |
| Sep 30, 2021 | 403.11 Mn |